Effect of mosapride on glycemic control and incretin secretion

Effect of mosapride on glycemic control and incretin secretion - Effect of mosapride on incretin secretion

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000007292

Enrollment

Registered

2012-02-17

Start date

2013-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dibetes

Interventions

Control: no medication Mosapride: administration of mosapride

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with type 2 diabetes and healthy subjects

Exclusion criteria

Exclusion criteria: taking another medicine to improve gastric movement

Design outcomes

Primary

Measure	Time frame
Plasma glucose, serum insuin and glucagon and plasma incretin levels	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026